Spots Global Cancer Trial Database for rubitecan
Every month we try and update this database with for rubitecan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas | NCT00005874 | Gastrointestina... Sarcoma Small Intestine... | rubitecan | - | National Cancer Institute (NCI) | |
| Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas | NCT00005870 | Pancreatic Canc... | fluorouracil gemcitabine hyd... mitomycin C rubitecan | 18 Years - | National Cancer Institute (NCI) | |
| Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas | NCT00005870 | Pancreatic Canc... | fluorouracil gemcitabine hyd... mitomycin C rubitecan | 18 Years - | National Cancer Institute (NCI) | |
| Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer | NCT00005869 | Pancreatic Canc... | gemcitabine hyd... rubitecan | 18 Years - | National Cancer Institute (NCI) | |
| Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer | NCT00006230 | Ovarian Cancer | rubitecan | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | NCT00006267 | Ovarian Cancer Primary Periton... | rubitecan | - | GOG Foundation | |
| Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas | NCT00005874 | Gastrointestina... Sarcoma Small Intestine... | rubitecan | - | National Cancer Institute (NCI) | |
| Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer | NCT00113256 | Pancreatic Canc... | Rubitecan | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Nitrocamptothecin in Treating Patients With Metastatic Melanoma | NCT00005875 | Melanoma (Skin) | rubitecan | 16 Years - | National Cancer Institute (NCI) | |
| Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer | NCT00005877 | Colorectal Canc... | rubitecan | - | National Cancer Institute (NCI) | |
| Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction | NCT00113113 | Tumors | Rubitecan | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | NCT00005873 | Breast Cancer | rubitecan | - | National Cancer Institute (NCI) | |
| Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme | NCT00005826 | Brain and Centr... | rubitecan | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | NCT00006267 | Ovarian Cancer Primary Periton... | rubitecan | - | GOG Foundation | |
| Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer | NCT00006267 | Ovarian Cancer Primary Periton... | rubitecan | - | GOG Foundation | |
| Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer | NCT00005872 | Lung Cancer | rubitecan | 18 Years - | National Cancer Institute (NCI) | |
| Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer | NCT00006082 | Lung Cancer | rubitecan | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction | NCT00113113 | Tumors | Rubitecan | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas | NCT00005870 | Pancreatic Canc... | fluorouracil gemcitabine hyd... mitomycin C rubitecan | 18 Years - | National Cancer Institute (NCI) | |
| Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract | NCT00006026 | Bladder Cancer Transitional Ce... Urethral Cancer | rubitecan | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer | NCT00005872 | Lung Cancer | rubitecan | 18 Years - | National Cancer Institute (NCI) | |
| Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer | NCT00005871 | Pancreatic Canc... | fluorouracil rubitecan | 18 Years - | National Cancer Institute (NCI) | |
| Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery | NCT00005876 | Esophageal Canc... Gastric Cancer | rubitecan | 18 Years - | National Cancer Institute (NCI) | |
| Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer | NCT00005872 | Lung Cancer | rubitecan | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
